Skip to content
Research Article Open access CC BY 4.0

Multisystemic Inflammatory Syndrome in Children: A Retrospective Study

E. Bahous, A. Ayad, R. Abilkassem, A. Ourrai, A. Hassani, A. Agadr

Asian Journal of Pediatric Research · pp. 14–27 · Published 18 Nov 2022

10.9734/ajpr/2022/v10i4203

Abstract

Introduction: Pediatric Multisystem Inflammatory Syndrome linked to temporal with SARS-Cov2 is a new hyper inflammatory disorder that affects children with Covid-19 infection. It usually occurs 2 to 6 weeks following illness or exposure. Materials and Methods: Descriptive retrospective study of a cohort of 11 patients with MIS-C treated in the pediatric department of the Mohamed V military hospital in Rabat between December 2020 and September 2021. We analyzed the epidemiological, clinical, biological, imaging, therapeutical and evolutionary data of our patients. Results: The average age is 9 years; the sex ratio is 1,2. The average exposure gap is 3.7 weeks. All patients presented with fever with multivisceral involvement, 81% presented digestive signs, 100% mucocutaneous signs, 63% cardiac signs and 54% neurological signs. Inflammatory markers were consistently high. Anemia (91%), neutrophilic leukocytosis (91%), lymphopenia (73%) are constant. The Covid-19 RT-PCR was negative and the SARSCov2 IgG serology testing was positive in all our patients. 54% of our cases have echocardiographic signs. Treatment was based on polyvalent intravenous immunoglobulins (IVIG) in all cases associated with corticosteroid therapy in 45% of cases and antiplatelet therapy in 91% of cases. The outcome was favorable in all of our patients. Conclusion: MIS-C should be considered in children with fever, rash, headache, tachypnea, and gastrointestinal symptoms such as vomiting, diarrhea, and abdominal pain. Cardiogenic shock is the main complication. IVIG and systemic corticosteroid therapy are the fundament of treatment.

Multisystemic inflammatory syndrome children SARS-CoV-2 clinical cases

References (29)

  1. 1 Endothelial cell infection and endotheliitis in COVID-19 [DOI]
  2. 2 Autoantibodies against type I IFNs in patients with life-threatening COVID-19 [DOI]
  3. 3 Multisystem Inflammatory Syndrome in U.S. Children and Adolescents [DOI]
  4. 4 Hyperinflammatory shock in children during COVID-19 pandemic [DOI]
  5. 5 An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study [DOI]
  6. 6 Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 [DOI]
  7. 7 Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 [DOI]
  8. 8 [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].
  9. 9 Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc [DOI]
  10. 10 COVID-19–Associated Multisystem Inflammatory Syndrome in Children — United States, March–July 2020 [DOI]
  11. 11 Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial [DOI]
  12. 12 Children with Covid-19 in Pediatric Emergency Departments in Italy [DOI]
  13. 13 Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort [DOI]
  14. 14 Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study [DOI]
  15. 15 Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study [DOI]
  16. 16 A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process [DOI]
  17. 17 Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children [DOI]
  18. 18 SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020 [DOI]
  19. 19 A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection [DOI]
  20. 20 Immunopathogenesis and immunotherapy of multiple sclerosis [DOI]
  21. 21 Corticosteroids for viral myocarditis [DOI]
  22. 22 Inhibition of Cell Adhesion by Antibodies to Arg-Gly-Asp (RGD) in Normal Immunoglobulin for Therapeutic Use (Intravenous Immunoglobulin, IVIg) [DOI]
  23. 23 Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action [DOI]
  24. 24 BAFF, a New Target for Intravenous Immunoglobulin in Autoimmunity and Cancer [DOI]
  25. 25 Demographic and Clinical Factors Associated With Death Among Persons <21 Years Old With Multisystem Inflammatory Syndrome in Children—United States, February 2020–March 2021 [DOI]
  26. 26 Multisystem Inflammatory Syndrome in Children (MIS-C): [DOI]
  27. 27 Cochrane Database of Systematic Reviews [DOI]
  28. 28 Centers for Disease Control and Prevention [DOI]
  29. 29 Childhood Multisystem Inflammatory Syndrome — A New Challenge in the Pandemic [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

58

Page views

0

PDF downloads

27

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.